

Enterococcal endocarditis — a case treated with teicoplanin and amoxicillin

P L Botha, M C Struwig, W de Vries, J Hough,
L J Chalkley

The study aimed to determine the antibacterial therapy effective in the cure of endocarditis caused by *Enterococcus faecalis* resistant to clinically achievable levels of vancomycin. Isolation of the causative enterococcus had been achieved by direct inoculation of the resected valve into the culture medium in theatre. The patient was known to have had an aortic valve defect since childhood and had recently undergone splenectomy following trauma. Blood cultures were negative prior to valve replacement. A perivalvular abscess was noted at operation. *In vitro* minimal bactericidal results and serum activity were the basis of the postoperative choice of drugs. The minimal bactericidal level of teicoplanin was 250 µg/ml and that of amoxicillin 64 µg/ml. Neither is achievable with the advocated dosage. A combination of these two cell-wall-active agents successfully eliminated the infection. Acting at two different sites in the synthesis of the bacterial cell wall, teicoplanin and amoxicillin were found to be bactericidal *in vitro* at the trough levels of the antibiotics in the serum. The patient recovered fully.

S Afr Med J 1998; **88**: 564-565.

While all around there are reports¹⁻³ of clinical isolates of heteroresistant enterococci, there is a dearth⁴ of publications on antibiotic susceptibility profiles of enterococci in South Africa.

Clinical findings

A 39-year-old farmer with known aortic incompetence of rheumatic origin was admitted with low-grade fever and complaints of tiring easily. Six months previously he had been treated for infective endocarditis elsewhere and more recently he had had a splenectomy after trauma. On current admission, the typical murmur of aortic incompetence was

present as well as an Austin Flint murmur over the mitral area. The left ventricle was enlarged both clinically and on sonar examination, and there was a vegetation on the aortic valve. ECG confirmed left ventricular enlargement. Chest radiography also confirmed cardiomegaly and grade I pulmonary venous hypertension. On sonar the left ventricular diameter was 5.3 cm with an increased diastolic and systolic muscle thickness of 14 mm and 16 mm, respectively. Left ventricular function was normal with an ejection fraction of 67%. The patient was classified as NYHA class III. Blood cultures did not yield any isolates and empirical treatment was commenced with penicillin G (6 million units 6-hourly) and amikacin (500 mg 12-hourly intravenously) for 6 weeks. Because of the symptoms, the state of the left ventricle and the vegetation it was decided to proceed with an aortic valve replacement under ampicillin cover.

On 16 July 1996 a median sternotomy was undertaken. The patient underwent cardiopulmonary bypass, and the aorta was cross-clamped and opened longitudinally. Blood cardioplegia was induced directly in the coronary arteries. The aortic valve was grossly abnormal with thickened edges, and a large vegetation was present. The valve was excised and placed aseptically directly into a wide-mouthed container holding Robertson's meat medium. A Carbomedics mechanical replacement valve (size 25) was placed in the supra-annular position with single non-absorbable sutures. It was noted that a perivalvular abscess was present in relation to the left right commissure. The aorta was closed, the heart de-aired and the patient was weaned from cardiopulmonary bypass without any problems and on minimal inotropic support. He was transferred to the ICU where he was ventilated for 16 hours and then extubated. On day 2 he was transferred to the ward. He continued to experience a low-grade fever and, when mobilised, experienced dyspnoea on the slightest exertion. On the basis of microbiological results of the valve culture he was given amoxicillin 1 g, 8-hourly and 3 doses of teicoplanin 400 mg 12-hourly, after which the dosage was reduced to 400 mg daily.

Within days the patient's condition improved and after 2 weeks of combination therapy he was discharged on oral amoxicillin for a further 4 weeks. Follow-up 6 months later found him to be in excellent health.

Microbiology

Three sets of Bactec blood cultures failed to culture the causative organism. From the resected valve in the Robertson's meat medium, which had been incubated at 37°C immediately and left undisturbed until turbidity appeared, *Enterococcus faecalis* was isolated on the 4th day and identified according to standard procedures⁵ as well as by polymerase chain reaction (PCR).¹ Primers were used to amplify the species-specific gene *ddl_E faecalis*.

In addition the enterococcus was found to be resistant to a number of antibiotics usually prescribed for endocarditis. Minimal inhibitory concentrations (MICs) were determined on Mueller-Hinton agar⁶ according to the National Committee of Clinical Laboratory Standards (NCCLS) agar dilution method (Table I).

Departments of Medical Microbiology and Cardiothoracic Surgery,
Universitas Hospital and University of the Orange Free State,
Bloemfontein

P L Botha, MMed (Path)

M C Struwig, MMed Sc

L J Chalkley, PhD, FIBMS

W de Vries, MMed (Card Thor Surg)

J Hough, MMed (Card Thor Surg), FCS (SA)

Table 1. *E. faecalis* isolate v. nine antimicrobial agents

	MIC	MBC
Gentamicin	16 µg/ml	
Tobramycin	16 µg/ml	
Amikacin	256 µg/ml	
Kanamycin	> 1 024 µg/ml	
Streptomycin	> 1 024 µg/ml	
Ampicillin	1 µg/ml	64 µg/ml
Ciprofloxacin	0.25 µg/ml	
Vancomycin	0.25 µg/ml	> 256 µg/ml
Teicoplanin	≤ 0.01 µg/ml	128 µg/ml

MBC = minimum bactericidal concentration.

Forty-eight hours after commencement of amoxycillin and teicoplanin therapy, the bactericidal activity of the patient's serum (drawn after stabilisation) was estimated. Bacteriostatic activity was demonstrated at a dilution of 1:32 and bactericidal activity at 1:4.

Further examination of the enterococcus by PCR:¹⁷

40 cycles of 94°C for 25 seconds, 49°C for 30 seconds, 70°C for 60 seconds in a Perkin Elmer 9600 GeneAmp thermal cycler using primers for the *ddl_{E faecalis}* gene: E₁ 5¢ATCAAGTACAGTTAGTCT and E₂ 5¢ACGATTCAAAGCTAACTG the *vanA* gene: UP5¢ATGAATAGAATAAAAAGTTGCAATAC and DOWN5¢CCCCTTTAACGCTAATACGAT as well as the *vanB* gene: B₁ 5¢ATGGGAAGCCGATAGTC and B₂ 5¢GATTCGTTCCCTCGACC.

Results: *vanA* and *vanB* PCR were both negative.

Discussion

Separately, neither the teicoplanin nor the amoxycillin levels achievable clinically would have been bactericidal, according to the *in vitro* results. In combination these two cell-wall-active agents, acting at different points in bacterial cell wall synthesis, proved bactericidal. The choice was made on the basis of the laboratory results and the fact that teicoplanin has outstanding penetration into cardiac muscle,⁸ especially important in view of the abscess noted at operation. The pharmacokinetics of teicoplanin, which has a long half-life, is another clinically important property. The basis of the postoperative choice of drugs rested on the *in vitro* minimal bactericidal results and the serum activity. Carbon⁹ has recently stressed the importance of initial high concentrations above the MIC of the infecting organism in experimental endocarditis. This has been corroborated by Martin *et al.*¹⁰ in the clinical situation.

The favourable outcome enabled the patient to resume the strenuous occupation of farming. The purpose of this case report is to make South African clinicians aware that resistant enterococci are emerging here and that classic therapy with a penicillin and an aminoglycoside is not necessarily curative anymore.


Hoechst Marion Roussel — per Ingeborg Glietenberg, who acted as intermediary — were generous in importing and donating a sufficient supply of teicoplanin (Targocid) for the treatment of this patient. The technical skills and willing

assistance of Johan Hefer, Cillie Jordaan and Marina Snyman are gratefully acknowledged. Thanks also to Anneke van der Spoel van Dijk, who skillfully produced the final document. The superintendent, Dr G van Zyl, is thanked for permission to publish these case findings.

REFERENCES

1. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to species level of clinically relevant enterococci by PCR. *J Clin Microbiol* 1995; **33**: 24-27. [Published erratum *ibid.* 1434].
2. Eliopoulos GM. Antibiotic resistance in *Enterococcus* species: An update. *Curr Clin Top Infect Dis* 1996; **16**: 21-51.
3. Lee PY, Das SS. Endocarditis due to high level gentamicin resistant *Enterococcus faecalis*. *Postgrad Med J* 1995; **71**: 117-119.
4. Huygens F, Lewis AI. Prevalence of penicillin, ampicillin and high level gentamicin resistance among enterococci. *S Afr J Epidemiol Infect* 1995; **10**: 108-110.
5. Facklam RR, Sahn DF. *Enterococcus*. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Tenover RH, eds. *Manual of Clinical Microbiology*. 6th ed. Washington, DC: American Society for Microbiology, 1995: 308-314.
6. National Committee of Clinical Laboratory Standards. *Performance Standards for Antimicrobial Susceptibility Testing* (M100-S4). Villa Nova: NCCLS, 1992.
7. Miele A, Bandera M, Goldstein BP. Use of primers selective for vancomycin resistance genes to determine *van* genotype in enterococci and to study gene organization in *VanA* isolates. *Antimicrob Agents Chemother* 1995; **39**: 1772-1778.
8. Lorian V. *Antibiotics in Laboratory Medicine*. Baltimore: Williams & Wilkins, 1991: 867.
9. Carbon C. The pharmacodynamics of endocarditis treatment strategies (Abstract 3046). 20th International Congress of Chemotherapy, Sydney, Australia, 29 June - 3 July 1997.
10. Martin C, Bourget P, Alaya M, *et al.* Teicoplanin in cardiac surgery: Intra-operative pharmacokinetics and concentrations in cardiac and mediastinal tissues. *Antimicrob Agents Chemother* 1997; **41**: 1150-1155.

Accepted 30 Dec 1997.



Rationing: Talk and Action in Health Care

November '97, paperback, 234 x 156 mm, 280 pp, R297

It is simply not possible to provide people with all the health care they need. Rationing is inevitable and the public must play a major role in the debate.

This unique publication is about talk and action in health care rationing. The King's Fund has joined forces with the BMJ Publishing Group to present the latest thinking and practical experience in rationing today. Six controversial statements are proposed and opposed by internationally respected experts in the book's first "talk" section. The action taken by New Zealand and Sweden described in the second section shows how the theory can and must be put into practice. This comprehensive discussion of the most pressing dilemma in medicine world wide is essential reading for anybody interested in the future of health care.

MASA Multimedia, Private Bag X1, Pinelands 7430. Tel: (021) 531-3081, Fax: (021) 531-4126.